Treats acute, uncomplicated influenza A and B. ANDA 208578, held by Zydus Pharms. Oseltamivir Phosphate.
As of Nov 16, 2026, ANDA 208578 (Oseltamivir Phosphate), held by Zydus Pharms, was first approved by FDA on Feb 24, 2017, with 5 approved supplements and 0 published complete response letters.
Oseltamivir Phosphate is an influenza neuraminidase inhibitor (NAI) indicated for: Treatment of acute, uncomplicated influenza A and B in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. Prophylaxis of influenza A and B in patients 1 year and older. Limitations of Use: Not a substitute for annual influenza vaccination. Consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use. Not recommended for patients with end-stage renal disease not undergoing dialysis. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 24, 2017 | Original application | Approved | None posted |
| Oseltamivir PhosphateEQ 30MG BASE · capsule;oral | Oseltamivir Phosphate | Rx |
| Oseltamivir PhosphateEQ 45MG BASE · capsule;oral | Oseltamivir Phosphate | Rx |
| Oseltamivir PhosphateEQ 75MG BASE · capsule;oral | Oseltamivir Phosphate | Rx |
| Mar 3, 2025 | Supplement 11Labeling · Standard review | Approved | None posted |
| Mar 3, 2025 | Supplement 9Labeling · Standard review | Approved | None posted |
| Mar 3, 2025 | Supplement 6Labeling · Standard review | Approved | None posted |
| Mar 3, 2025 | Supplement 5Labeling · Standard review | Approved | None posted |
| Mar 3, 2025 | Supplement 4Labeling · Standard review | Approved | None posted |
| Feb 24, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters